以CXC趨化因子受體4爲標靶之奈米粒子用於製備治療肝癌與抑制肝癌轉移之醫藥組成物的用途

專利類型

發明

專利國別 (專利申請國家)

中華民國

專利申請案號

104111300

專利證號

I 556830

專利獲證名稱

以CXC趨化因子受體4爲標靶之奈米粒子用於製備治療肝癌與抑制肝癌轉移之醫藥組成物的用途

專利所屬機關 (申請機關)

國立清華大學

獲證日期

2016/11/11

技術說明

本發明係關於一種CXC趨化因子受體4(CXCR4)標靶奈米粒子用於製備治療肝癌與抑制肝癌轉移之醫藥組成物的用途。本發明以CXCR4拮抗劑AMD3100作為標靶分子修飾脂質載體形成奈米粒子，可促進所包覆之物質(如：抗血管新生藥物或具抗血管新生功效之核酸)於肝癌細胞的累積與吸收，更可增加肝癌細胞對該藥物或該具抗血管新生功效之核酸的敏感性，對抑制肝癌細胞之血管新生與腫瘤發展具有加成效應。再者，本發明CXCR4標靶奈米粒子可有效抑制肝癌細胞的轉移。該醫藥組成物係為一針劑，故，可應用於臨床肝癌的治療。 Provided is a use of CXCR4-targeted nanoparticle for the manufacture of pharmaceuticl composition for treatment of liver cancer and inhibition of metastasis. CXCR4 anatognist, AMD3100, is used as a targeting molecule to modify a lipid carrier for the formation of nanoparticle carrying anti-angiogenesis drug or anti-angiogentic nucleotide. Such nanoparticle can enhance the accumulation and uptake of said drug and nucleotide in liver cancer cells as well as sensitize the liver cancer cells to treatment of said drug and nucleotide, providing a synergistic suppression of angiogenesis and tumor progression. Furthermore, the CXCR4-targeted nanoparticle can effectively inhibit metastasis of liver cancer. The pharmaceutical composition is an injectable composition; hence, is suitable for clinical application for the treatment of liver cancer.

備註

連絡單位 (專責單位/部門名稱)

智財技轉組

連絡電話

03-5715131-62219

網址